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Heart rate variability (HRV) is reduced in diabetes mellitus (DM) patients, suggesting dys-
function of cardiac autonomic regulation and an increased risk for cardiac events. The aim
of this paper was to examine the associations of blood glucose level (BGL), glycated hemo-
globin (HbA1c), and duration of diabetes with cardiac autonomic regulation assessed by
HRV analysis. Resting electrocardiogram (ECG), recorded over 20 min in supine position,
and clinical measurements of 189 healthy controls and 93 type 2 DM (T2DM) patients were
analyzed. HRV was assessed using several time-domain, frequency-domain, and non-linear
methods. HRV parameters showed a clear difference between healthy controls andT2DM
patients. Hyperglycemia was associated with increase in mean heart rate and decrease
in HRV, indicated by negative correlations of BGL and HbA1c with mean RR interval and
most of the HRV parameters. Duration of diabetes was strongly associated with decrease
in HRV, the most significant decrease in HRV was found within the first 5–10 years of the
disease. In conclusion, elevated blood glucose levels have an unfavorable effect on cardiac
autonomic function and this effect is pronounced in long-term T2DM patients. The most
significant decrease in HRV related to diabetes and thus presence of autonomic neuropathy
was observed within the first 5–10 years of disease progression.
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1. INTRODUCTION
Heart rate variability (HRV) is a commonly used tool to assess
the functioning of cardiac autonomic regulation. The auto-
nomic nervous system (ANS) regulates heart rate (HR) through
sympathetic and parasympathetic (vagal) branches where the
sympathetic activity increases HR and decreases HRV, whereas
parasympathetic activity decreases HR and increases HRV (1).
Two apparent components of HRV are the low frequency (LF,
ranging from 0.04–0.15 Hz) component mediated by both sym-
pathetic and parasympathetic nervous activities and the high
frequency (HF, 0.15–0.4 Hz) component mediated almost solely
by parasympathetic nervous activity (1, 2).
Heart rate variability is reduced in diabetes mellitus (DM)
patients, suggesting dysfunction of cardiac autonomic regulation,
which has been previously shown to be associated with increased
risk for adverse cardiac events (3). Cardiac autonomic neuropathy
(CAN), which results from damage to autonomic nerve fibers that
innervate the heart and blood vessels, is a serious complication of
DM (4). During progression of CAN, the parasympathetic nerve
fibers innervating the heart are affected before the sympathetic
nerve fibers leading to a reduced heart rate variability (5). Reduced
HRV is recognized as an early indicator of CAN, but reduction of
HRV has been observed also in patients without evidence of CAN
when using traditional tests such as the Ewing battery (2, 6, 7).
Standard time and frequency-domain analysis of HRV combined
with cardiovascular autonomic reflex tests are used in clinical
assessment of CAN (8), but recently several non-linear methods
for assessing CAN have been proposed (9, 10).
The pathogenesis of diabetic neuropathies is complex, but
long-lasting hyperglycemia is responsible for chronic metabolic
perturbations (mainly increased activation of the polyol path-
way and increased production of harmful metabolites) leading to
neuronal damage (7, 11–13). Therefore, the blood glucose targets
suggested for most patients with diabetes are fasting blood glu-
cose level (BGL) 7 mmol/L and glycated hemoglobin (HbA1c) 7%
(53 mmol/mol), but it is recommended that these blood glucose
targets should be individualized to meet patient needs (14).
Several studies on the association between BGL and HRV have
been conducted in order to better understand the autonomic
dysfunction related to diabetes, both with and without CAN.
In general, reduced HRV has been observed in diabetic patients
(15–17). In Ref. (16), the HF component of HRV was reduced in
subjects with DM. However, in Ref. (17), reduction of the LF com-
ponent of HRV was observed in diabetics as well as in subjects with
impaired fasting BGL. Furthermore, HRV has been shown to be
inversely associated with BGL, indicated by negative correlations
between both LF and HF component powers and BGL (17). In
addition, an increased LF/HF power ratio has been shown during
hyperglycemia in controls and diabetics without CAN (18).
Based on these studies, it has been suggested that cardiac auto-
nomic dysfunction is associated with impaired glucose tolerance
(IGT) tested with an oral glucose tolerance test, but not with
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impaired fasting glucose (7, 19). Nevertheless, effective glycemic
control plays a central role in reducing the risk of CAN, but the
associations between BGL and autonomic dysfunction need to be
further studied. Also, the timeline of these changes in ANS func-
tion should be investigated further to better understand the pro-
gression of CAN. In addition, the associations between autonomic
dysfunction and other risk factors, such as obesity, hypertension,
or increased cholesterol levels, need to be considered in future
studies.
The aim of the present study was to examine the associations
between hyperglycemia and ANS dysfunction in patients with type
2 DM (T2DM). ANS function was assessed by using a wide range
of time-domain, frequency-domain, and non-linear HRV analy-
sis methods. Glycemic control was determined by fasting BGL
and HbA1c measurements. HbA1c is commonly used to iden-
tify average plasma glucose concentration over 3 months prior to
the measurement. In addition, other risk factors such as body
weight, blood cholesterol, and blood pressure were also consid-
ered. Furthermore, association of the disease duration with ANS
dysfunction in diabetes was examined to reveal the timeline of
changes in cardiac autonomic regulation.
2. MATERIALS AND METHODS
2.1. SUBJECTS AND RECORDINGS
189 healthy controls and 93 type 2 diabetes mellitus patients who
were participants of a health screening clinic at Charles Sturt Uni-
versity were included in the study. Some of the subjects were
measured more than once (1–5 visits per subject during 2002–
2012, on average two visits per each diabetic subject) resulting in a
total of 273 control and 199 T2DM measurements. Subjects with
history or clinical evidence of heart failure, atrial fibrillation, or
myocardial infarction were excluded from the study. None of the
diabetic patients showed clinical evidence of CAN using the Ewing
battery of tests (20).
Fasting blood samples were taken to measure blood glu-
cose, glycated hemoglobin, and blood cholesterol. BGL was mea-
sured clinically using an Accu-Chek Advantage II glucometer
(Roche Australia P/L). Fasting plasma HbA1c, total cholesterol
(TC), triglycerides (TG), and high-density lipoprotein choles-
terol (HDL) were measured by standard techniques. TC and TG
were determined with a commercial enzymatic kit. HDL was
determined by immunoinhibition assay. Low-density lipopro-
tein cholesterol (LDL) was calculated according to the Friede-
wald formula. Systolic and diastolic blood pressure (SBP and
DBP) were measured in a supine position using a Welch–Allyn
blood pressure recorder. Use of anti-hypertensive drugs (ACEI,
ARB, lˆ2-blockers), antidepressants (SNARI, SSRI, Amitriptyline
hydrochloride), or anti-cholesterol drugs (statins) were identi-
fied. The clinical characteristics of the healthy controls and T2DM
patients who participated in the study are summarized on Table 1.
A supine resting electrocardiogram (ECG) was recorded over
20 min at 400 Hz sampling rate using a lead II configuration
(Maclab ADInstruments, Australia) for all participants. An adap-
tive QRS detector algorithm was applied to extract the beat-to-beat
RR intervals from the ECG data. The very low frequency trend
components (frequencies below 0.04 Hz) were removed from the
RR interval time series by using a smoothness priors method (21).
Furthermore, the non-equidistantly sampled RR series were inter-
polated (4 Hz cubic spline interpolation) to have evenly sampled
data for spectral analysis. Respiratory frequency was estimated
from the ECG R-wave amplitude changes and utilized in HF
component estimation.
The study was approved by the Charles Sturt University Human
Ethics Committee and written informed consent was obtained
from all participants.
2.2. HEART RATE VARIABILITY ANALYSIS
HRV was assessed using several time-domain, frequency-domain,
and non-linear analysis parameters, by following the guide-
lines given in Ref. (2). The frequency-domain parameters were
computed from the detrended and interpolated (equidistantly
sampled) RR interval series, whereas time-domain and non-
linear parameters were computed from the detrended but not
interpolated RR series.
The time-domain parameters included the mean RR interval,
standard deviation of normal-to-normal RR intervals (SDNN),
root mean square of successive RR interval differences (RMSSD),
and percentage of successive RR intervals with difference bigger
than 50 ms (pNN50). Two geometric measures computed from
the RR interval histogram were also considered. These were the
HRV triangular index (HRVi), which gives the total number of RR
intervals within the time series (integral of the histogram) divided
by the number of RR intervals at the modal bin of the histogram,
and the triangular interpolation of RR interval histogram (TINN),
which is the baseline width of a triangle fitted to the histogram.
The frequency-domain parameters included LF and HF com-
ponent powers and total spectral power. LF and HF powers were
also computed in normalized units, which were obtained by divid-
ing the absolute powers with total spectral power and multiplying
by 100 to give values as a percentage. The frequency-domain para-
meters were extracted from the RR interval spectrum, which was
estimated using autoregressive (AR) spectrum estimation with
model order 20. The advantage of AR spectrum is that the spec-
trum estimate can be decomposed into distinct components using
spectral factorization (22). The LF and HF component pow-
ers were computed from the factorized spectrum by summing
the spectral components centered within 0.04–0.15 and 0.15–
0.5 Hz, respectively. The upper limit of HF band was increased
to 0.5 Hz because the respiratory frequency of some subjects was
over 0.4 Hz. Subjects with respiratory frequency below 0.15 Hz was
excluded.
Furthermore, four commonly used non-linear HRV methods
were used to assess HRV. The Poincaré plot is a scatter plot between
successive RR intervals and provides indexes for short-term vari-
ability (SD1) and long-term variability (SD2), where both SD1
and SD2 are non-linearly connected to time-domain parameters
(23). Sample entropy (SampEn) is a commonly used measure of
signal complexity and was computed using an embedding dimen-
sion of m= 2 and tolerance of 0.2 times the standard deviation
of the time series (24). Correlation dimension is also a mea-
sure of signal complexity and is expected to carry information
of the minimum number of dynamic variables needed to model
the underlying system (25). Finally, detrended fluctuation analysis
(DFA) is a measure of self-affinity of a signal, separated here into
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Table 1 | Clinical characteristics of the healthy control subjects andT2DM patients participating the study.
Variable Units Healthy controls (N =273) T2DM patients (N =199) pa
Median (50% CI) n (males, %) Median (50% CI) n (males, %)
Age Years 62 (54–70) 273 (38) 66 (59–71) 199 (44) **
Duration of diabetes Years – – 8 (4–12) 199 (44) –
BMI kg/m2 26.5 (23.9–29.9) 268 (38) 29.5 (26.2–33.7) 191 (45) ***
BGL mmol/l 4.8 (4.3–5.3) 267 (38) 7.2 (5.7–10.2) 189 (44) ***
HbA1c % 5.6 (5.4–5.8) 77 (36) 6.8 (6.2–7.6) 121 (43) ***
mmol/mol 38 (36–40) 77 (36) 51 (44–60) 121 (43) ***
Total cholesterol (TC) mmol/l 5.1 (4.6–5.7) 178 (36) 4.4 (3.5–5.3) 118 (47) ***
LDL mmol/l 3.1 (2.6–3.5) 115 (34) 2.4 (1.6–3.1) 103 (48) ***
HDL mmol/l 1.4 (1.1–1.7) 172 (35) 1.2 (1.0–1.4) 115 (49) ***
Triglyceride mmol/l 1.0 (0.8–1.6) 127 (35) 1.6 (1.1–2.2) 112 (47) ***
TC/HDL – 3.6 (3.0–4.6) 172 (35) 3.6 (3.0–4.2) 115 (49) N.S.
SBP mmHg 126 (118–140) 269 (38) 132 (125–145) 198 (44) ***
DBP mmHg 79 (70–83) 269 (38) 79 (71–84) 198 (44) N.S.
Medicationb
Anti-hypertensive 63 (30) 139 (40) ***
Antidepressant 17 (18) 19 (32) N.S.
Anti-cholesterol 8 (25) 22 (68) **
***p≤0.0001; **p≤0.001; *p≤0.027.
Values are expressed as Median (50% confidence interval).
aMann–Whitney U test for the difference between control subjects and T2DM patients.
bNumber of subjects using one or more of the listed medication types (the difference between the groups evaluated using cross-tabulation and Chi-squared statistics).
short-term (α1, 4–16 beat fluctuations), and long-term (α2, 16–64
beat fluctuations) fluctuations within the RR data (26).
2.3. STATISTICAL ANALYSIS
Non-parametric tests were used because some of the HRV parame-
ters were not normally distributed. Data are presented as median
values (50% confidence interval). The Mann–Whitney U test was
used to test the group differences between healthy control sub-
jects and T2DM patients as well as for testing differences between
T2DM patients grouped according to disease duration, measured
blood glucose, or HbA1c. These group differences were tested
mainly to discover the most significant differences in HRV para-
meters between the groups, but also the clinical characteristics
were tested to observe differences between healthy controls and
T2DM patients. In case of categorical variables (i.e., medication
use), cross-tabulation and Chi-squared statistics were used to test
the difference between the groups. Furthermore, Spearman’s rank
correlation coefficient was applied for measuring statistical depen-
dence between HRV parameters and disease duration, BGL, and
HbA1c within the diabetes group. Finally, stepwise linear regres-
sion analysis was applied to determine whether there were inde-
pendent associations between HRV parameters and BGL, HbA1c,
and disease duration. When evaluating the associations of HRV
with BGL and HbA1c, the influence of disease duration, and med-
ication use were taken into account by adding them as descriptive
parameters in the regression model.
The significance level was set to α= 0.05 and corrected for
multiple comparisons with false discovery rate (FDR) to yield a
threshold of p≤ 0.027.
3. RESULTS
The clinical characteristics of the measured subjects are sum-
marized in Table 1. The diabetes group was on average 4 years
older and with a higher BMI compared to healthy control
subjects. Within the T2DM patients, BGL varied between 3.3
and 20.1 mmol/L and HbA1c between 5.2 and 13.0% (33–
119 mmol/mol), both of these indexes being significantly higher
for diabetes group compared to controls. The diabetes group
also had lower TC, LDL cholesterol, and HDL cholesterol, but
higher triglycerides, compared to controls. Furthermore, the dia-
betes group had higher systolic blood pressure and the use of
anti-hypertensive and anti-cholesterol medications were more
common within the diabetes group compared to controls.
HRV analysis of the 20-min resting measurements was then
performed as described in Section 2. RR interval data and power
spectral estimates for three representative subjects are shown in
Figure 1. The very low frequency trend components removed
from the RR interval series prior to analysis are illustrated over
the RR interval data. The mean RR interval length and the powers
of the LF and HF components are highest for the healthy control
(Figure 1A) and lowest for theT2DM patient with longer disease
duration for similar age (Figure 1C).
HRV analysis results are summarized in Table 2, which presents
the median (50% confidence interval) values of each HRV para-
meter for healthy controls and T2DM patients. Multiple linear
regression was applied to adjust the HRV parameter values for
the confounding effects of gender, age, and BMI. Most of the HRV
parameters showed a clear difference between control and diabetic
subjects. It is observed that HR is increased (mean RR decreased)
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FIGURE 1 | RR interval time series (bold line showing the removed
trend) and AR spectrum estimates for healthy control subject (A),
T2DM patient diagnosed 6 years prior to measurement (B), andT2DM
patient diagnosed 13 years prior to measurement (C).
and HRV decreased in T2DM patients when compared to controls.
However, normalized LF and HF powers did not show significant
difference between the diabetes group and healthy controls.
The effect of glycemia and disease duration on different HRV
parameters were then evaluated within the data of T2DM patients
by computing Spearman’s rank correlation coefficients between
each HRV parameter and BGL, HbA1c, and disease duration.
Spearman’s correlations are presented in Table 2. Mean RR inter-
val and most of the HRV parameters were negatively correlated
with both BGL and HbA1c. However, DFA α2 showed a signifi-
cant positive correlation with BGL and sample entropy a positive
correlation with HbA1c. Most of the HRV parameters showed
also a strong negative correlation with disease duration, whereas
mean RR showed only a small negative correlation with disease
duration.
The effect of glycemia on selected HRV parameters is further
illustrated in Figures 2A,B. In order to observe HRV changes
related to glycemia, the diabetes group was divided into four sub-
groups according to BGL (3–5.5, 5.6–7, 7.1–11, and>11 mmol/L)
and HbA1c (4–5.6, 5.7–6.4, 6.5–7.5, and >7.5%). The number of
measurements within each subgroup varied between 32 and 66,
except for the lowest HbA1c subgroup, which consisted of only
four measurements. The healthy subjects were divided only into
the first two glycemic (3–5.5 and 5.6–7 mmol/L) subgroups. No
remarkable changes were observed between the first two glycemic
(control or diabetes) subgroups, i.e., when BGL is below 7 mmol/L
and HbA1c below 6.4% (46 mmol/mol), but mean RR interval and
HRV were decreased for the two highest glycemic subgroups for
diabetic patients.
Correspondingly, the effect of disease duration on HRV is illus-
trated in Figure 2C. The diabetes group was divided into five
subgroups according to the time after the diagnosis. The number
of measurements within each subgroup varied between 17 and
66. Mean RR interval did not change significantly, whereas a sub-
stantial reduction in HRV was observed as a function of disease
duration. Moreover, the decrease in HRV took place mainly during
the first 5–10 years of the disease.
Associations between BGL, HbA1c, disease duration, and other
clinical characteristics provided in Table 1 were next examined
using Spearman’s correlation. BGL was naturally associated with
HbA1c, but also with disease duration (r = 0.185, p= 0.011),
triglyceride level (r = 0.201,p= 0.036), and use of anti-cholesterol
medication (r = 0.145,p= 0.046). HbA1c was also associated with
disease duration (r = 0.226, p= 0.013) but not with any other
clinical measure except BGL. In addition, disease duration was
associated with LDL (r = -0.239,p= 0.015) and DBP (r =−0.187,
p= 0.008). These main associations within the clinical variables
are illustrated in Figure 3.
Since glycemic values (BGL and HbA1c) were associated with
disease duration and medication use, a stepwise linear regression
was applied to systematically examine:
1. The independent associations of different HRV parameters
with BGL, HbA1c, and disease duration.
2. The independent associations of HRV parameters with BGL
and HbA1c after including disease duration and medication
use in the model as descriptive parameters.
Among the HRV parameters, the best descriptive parameters
for BGL were found to be mean RR, SampEn, and absolute LF
power. When disease duration and medication use were included
in the model as descriptive parameters, Mean RR, SampEn, and
LF power remained as the three most significant descriptive para-
meters for BGL. Similarly, the best descriptive HRV parameter
for HbA1c was total spectral power and the model accuracy was
not significantly improved by adding any other HRV parameter.
When disease duration and medication use were included in the
model, disease duration came out as the sole significant descriptive
parameter for HbA1c. Finally, the sole significant descriptive HRV
parameter for disease duration was total spectral power, and when
medication use was included in the model, total spectral power
remained as the sole significant descriptive parameters.
The associations of mean RR and total spectral power with
BGL and disease duration are further illustrated in Figure 4, which
shows third order polynomial surface fits on the individual data
points. Also from this Figure, it is observed that the decrease of
mean RR is stronger along the BGL axis, whereas decrease in total
power is more strongly associated with disease duration.
4. DISCUSSION
In this paper, the associations of cardiac autonomic regulation
assessed by HRV analysis with BGL, HbA1c, and duration of dia-
betes in T2DM patients were examined. In summary, HR was
increased and HRV decreased in hyperglycemia. The mean RR
interval decreased (HR increased) consistently as a function of
BGL and HbA1c as shown by Table 2 and Figure 2. Most of the
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Table 2 | HRV parameter values for healthy control subjects andT2DM patients and their correlations with duration of diabetes, BGL, and
HbA1c withinT2DM patients.
HRV parameter (units) Healthy controls vs.T2DM patients Correlation coefficientsb
Control (N =273)
Median (50% CI)
T2DM (N =199)
Median (50% CI)
pa BGL (mmol/l) HbA1c (%) Duration (years)
Mean RR (ms) 963 (891–1051) 903 (804–1015) *** −0.246** −0.195* −0.166*
SDNN (ms) 25.1 (19.0–31.9) 20.3 (14.2–27.7) *** −0.218* −0.253* −0.383***
RMSSD (ms) 25.0 (18.1–33.1) 19.1 (12.5–28.0) *** −0.229* −0.250* −0.346***
pNN50 (%) 3.56 (1.11–10.27) 2.02 (0.42–5.18) ** −0.247** −0.238* −0.267**
HRVi 6.71 (5.29–8.49) 5.81 (3.99–7.22) *** −0.238** −0.230* −0.398***
TINN (ms) 157 (119–214) 124 (91–171) *** −0.149 −0.250* −0.363***
LF power (dB) 25.4 (22.6–27.9) 23.1 (19.8–26.2) *** −0.186* −0.234* −0.372***
HF power (dB) 22.5 (19.7–25.8) 21.2 (16.6–24.6) ** −0.173* −0.204* −0.359***
Total power (dB) 27.9 (25.6–30.1) 25.9 (22.8–28.9) *** −0.197* −0.251* −0.418***
LF power (n.u.) 62.0 (49.5–73.7) 62.3 (47.8–74.2) N.S. 0.013 −0.053 −0.003
HF power (n.u.) 37.5 (25.7–50.2) 35.7 (25.1–51.4) N.S. −0.040 0.036 −0.034
SD1 (ms) 17.7 (12.8–23.4) 13.5 (8.9–19.8) *** −0.229* −0.250* −0.346***
SD2 (ms) 30.6 (23.0–39.4) 25.0 (18.1–33.7) *** −0.208* −0.252* −0.385***
SampEn 1.73 (1.55–1.85) 1.75 (1.62–1.88) N.S. −0.161* 0.227* 0.073
DFA, α1 1.00 (0.82–1.15) 1.01 (0.77–1.15) N.S. 0.060 −0.056 0.013
DFA, α2 0.35 (0.29–0.43) 0.41 (0.31–0.50) *** 0.205* 0.187 0.193*
D2 0.47 (0.16–1.02) 0.27 (0.06–0.57) ** −0.230* −0.209* −0.263**
***p≤0.0001; **p≤0.001; *p≤0.027.
HRV parameter values are expressed as Median (50% confidence interval), adjusted for age, gender and BMI.
aMann–Whitney U test for the difference between control subjects and T2DM patients.
bSpearman’s rank correlation coefficients for the statistical dependence between HRV parameters and BGL, HbA1c and disease duration (computed within the
diabetes group).
HRV parameters decreased as a function of BGL and HbA1c, but
normalized powers of LF or HF components were not associ-
ated with glycemia. This suggests that cardiac autonomic regu-
lation is reduced in hyperglycemia without significant change in
sympatho-vagal balance.
In the stepwise regression, the most significant descriptors for
BGL were Mean RR, SampEn, and LF power, whereas for HbA1c
total spectral power was the sole significant descriptive parame-
ter. The decrease of mean RR and LF power indicates that the
reduction of HRV in hyperglycemia could be dominated by the
sympathetic branch of the ANS in agreement with known physiol-
ogy, where increased BGL leads to increase in sympathetic nervous
activity (27). The LF component of HRV is also affected by barore-
flex activity, which is known to be reduced in diabetes but its
association with hyperglycemia is unknown.
In addition to linear measures, some of the non-linear measures
of HRV were associated with BGL and HbA1c. The Poincaré plot
indices SD1 and SD2 both decreased as a function of increased
BGL and HbA1c, which is understandable considering the con-
nections of these indices to time-domain measures of HRV (23).
One interesting finding was that sample entropy was the sec-
ond most significant descriptor (after mean RR) in the stepwise
regression analysis for BGL, indicating that hyperglycemia induces
changes in RR time series complexity, which is not detectable
by standard linear methods. However, while SampEn correlated
negatively with BGL, its correlation with HbA1c was positive. The
long-term correlations estimated by DFA α2 were also found to be
increased in hyperglycemia, but the reliability of this parameter
is not optimal when computed from short-term recordings (26)
and its values are overall lower due to detrending performed in this
study. An alternative explanation is that acute effects such as raised
BGL affect initially parasympathetic modulation, whereas chronic
hyperglycemia becomes more pronounced with increased sympa-
thetic modulation of the HR, which is reflected by the increased
SampEn and DFA α2.
It should be mentioned that the HRV values observed for the
lowest glycemic range may be affected by hypoglycemia, which is a
common side effect of medication and associated with adverse car-
diac outcomes possibly by affecting sympathetic nervous system
function (13).
HRV was also strongly associated with the duration of diabetes.
Mean RR interval, on the other hand, did not show consistent
changes as a function of disease duration. HRV was decreased as
a function of disease duration illustrated by significant negative
correlations between most of the HRV parameters and disease
duration (see Table 2). However in the stepwise regression analy-
sis, the sole significant descriptive parameter for disease duration
was the total spectral power. The appearance of total power as the
most significant descriptive parameter indicates that the overall
variability within the RR time series is reduced in diabetes. An
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FIGURE 2 | Box plots of selected HRV associations with BGL (A),
HbA1c (B), and duration of diabetes (C). On each box, the central
mark is the median, the edges of the box are the 25th and 75th
percentiles, and the whiskers extend to the most extreme
parameter values excluding outliers. Significant differences between
all the “boxes” (A,B) or between successive “boxes” (C) were
tested using the Mann–Whitney U test (***p≤0.001; **p≤0.01;
*p≤0.05).
interesting outcome of this study was that the most significant
decrease in HRV in T2DM patients happened within 5–10 years
after diagnosis, after which HRV seem to have reached a plateau.
This finding is in line with an earlier study where frequency of
autonomic neuropathy increased sharply after 5 years of follow-
up in T2DM patients (28). The observed plateau phase in HRV
after 10 years of follow-up requires further study as it has a bearing
on long-term therapy of type 2 diabetic patients and the relevance
of intensive insulin therapy.
Medication (anti-hypertensive, antidepressant, and anti-
cholesterol medications) did not influence significantly the cor-
relation results given in Table 2. After adjustment for medication,
HRV correlations with BGL were only slightly weaker (Mean
RR: r =−0.221, p= 0.002; pNN50: r =−0.215, p= 0.003; HRVi:
r =−0.228, p= 0.002). This was explained by the positive cor-
relation between BGL and use of anti-cholesterol medication
(r = 0.145, p= 0.046), because of which HRV results between
the diabetic patients averaged out when medication was included.
HRV correlations with HbA1c or disease duration did not change
significantly when computed with correction for medication.
Total cholesterol, LDL, and HDL values were all lower and
triglyceride levels were higher for the diabetic patients compared
to healthy controls. The different levels of cholesterol are partly
explained by the diabetic group using more commonly anti-
cholesterol medication compared to control subjects. Triglyceride
level was associated with BGL, but not with HbA1c or disease
duration. In addition, LDL was negatively correlated with disease
duration. The correlation between HbA1c and triglycerides also
needs further research with opposing findings being reported in
the literature but is a function of diabetes control and medica-
tion use as much as of age or diabetes duration (29). Moderate
increases in BGL above 5.5 mmol/L have been shown to lead to
changes in the redox state and cholesterol as well as triglyceride
levels and therefore atherosclerosis (30). HRV has previously been
shown by our group to be correlated with the Framingham risk
score for CVD disease, which includes presence of diabetes and
cholesterol level as risk factors and is directly correlated to the
TC/HDL ratio (31).
Although influence of age on HRV has been reported (32, 33),
the influence of diabetes duration has received less attention (34).
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FIGURE 3 | Box plots of most significant associations between clinical
characteristics, BGL, HbA1c, and duration of diabetes (***p≤0.001;
**p≤0.01; *p≤0.05). Descriptions as in Figure 2.
The current research indicates that HRV changes observed in
association with duration of diabetes are additive to any effects
of age and occur more prominently within the first 5 years of
diabetes (35). RMSSD and HF power showed a significant asso-
ciation with duration of diabetes up to 5–10 years indicating that
parasympathetic modulation is lost during this period, whereas
LF power was reduced significantly in the 10- to 15-year duration
group compared to less duration of diabetes, indicating loss of
sympathetic influence. These findings corroborate early findings
by Ewing and others who suggested that parasympathetic with-
drawal precedes sympathetic dysfunction in the modulation of
HR (20, 36, 37).
With respect to HbA1c and BGL, a Japanese study has shown
that optimal HbA1c and BGL levels to delay microvascular
complications in a 8-year follow-up study were HbA1c <6.5%
(48 mmol/mol) and BGL <6.1 mmol/L (38). Recent findings of
the United Kingdom Prospective Diabetes Study (UKPDS), Dia-
betes Complications and Control Trial (DCCT), and Australian
National Health and Medical Research Council (NHMRC) guide-
lines recommend a cut-off at 7%. However, this may depend on
type of diabetes, duration of diabetes, and comorbidities present
(39, 40). Our study indicates that a BGL below the American Dia-
betes Society cut-off has no effect on HRV changes. However, there
are significant effects once BGL rises above 5.6 mmol/L in HRV
measures indicating that lower BGL levels have beneficial effects
on cardiac health. Similarly, the greatest effect of increased HbA1c
occurred above a HbA1c value of 5.7% (39 mmol/mol), which is
lower than recommended by previous research but may indicate
FIGURE 4 | Polynomial least squares surface fits for the associations of
mean RR (top) and total power (bottom) with BGL and disease
duration.
that cardiac health is more sensitive to minor increases in HbA1c
compared to microvascular disease found in the retina or kidneys.
5. CONCLUSION
In summary, our findings indicate that elevated glycemic values
have an unfavorable effect on cardiac autonomic function and
this effect is pronounced in long-term T2DM patients. Hyper-
glycemia was associated with moderate increase in mean heart rate
and decrease in HRV, whereas duration of diabetes was strongly
associated with decrease in HRV. The most significant decrease in
HRV related to diabetes was observed to take place within the first
5–10 years of the disease.
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